Share

New Integrated Data Show Promise for Novel Thyroid Eye Disease Drug

New pooled data from Phase 2 and Phase 3 clinical trials further reinforce that teprotumumab-trbw significantly improves proptosis (eye bulging) and diplopia (double vision) for thyroid eye disease (TED) in patients in different subgroups, with most maintaining a long-term response. The results were published recently in The Lancet Diabetes & Endocrinology. Teprotumumab-trbw is a fully human...
Share

Increased Risk of Hearing Impairment with New TED Treatment

Small study finds 65% of patients taking teprotumumab report otologic symptoms. More patients than previously reported may experience hearing symptoms such as hearing loss or muffled hearing from a new treatment for thyroid eye disease TED), teprotumumab (Tepezza), according to a small study presented virtually at ENDO 2021. Teprotumumab, approved by the U.S. Food and...
Share

Combination Thyroid Hormone Therapies Treat Hypothyroidism Comparable to Levothyroxine

Treatment should be individualized for common thyroid condition, researchers say Treatment of hypothyroidism, which results from an underactive thyroid gland, should be individualized and consideration should be given to alternatives to the first-line therapy, including desiccated thyroid extract and combination therapy to replace the body’s two main thyroid hormones, thyroxine (T4) and triiodothyronine (T3), according...
Share

FDA Grants Orphan Drug Designation for Potential Treatment of Hypoparathyroidism

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to AZP-3601, Amolyt Pharma’s clinical candidate for the treatment of hypoparathyroidism. “We believe the FDA’s granting of Orphan Drug Designation to AZP-3601 reflects the agency’s recognition that new and more effective treatment options are needed for this serious endocrine disorder,” says Endocrine...
Share

Eureka 2020! Part IV – Top Endocrine Science According to JCEM Editors

jcem cover For the sixth year running, Endocrine News talks to editors from Endocrine Society publications to get the scoop on the top endocrine discoveries of 2020. In this fourth installment, we talk to The Journal of Clinical Endocrinology & Metabolism editors about what they think this year’s most significant studies were that will impact endocrine science...
Share

In the Mix: Combination Therapy for Hypothyroidism Gets Another Look

While evidence-based guidelines don’t encourage it, many endocrinologists recognize a need to give combination therapy a trial in some patients with hypothyroidism. Although treatment guidelines specify levothyroxine as the standard of care for hypothyroidism, many thyroid specialists acknowledge a dirty little not-so-secret: When pressed by an insistent patient, many clinicians find it prudent to explore...
Share

Cause & Effect: Patients with Obesity and Thyroid Function Testing

According to a new guideline from the European Society of Endocrinology, patients with obesity should be routinely tested for thyroid function. However, testing for other endocrine-related conditions should be guided by the presence of symptoms. The endocrine system and obesity can have a push-pull relationship. Some endocrine disorders — such as hypothyroidism and Cushing’s syndrome...

Endocrine News provides the latest news and research articles on thyroid conditions and treatment. For more info read this month’s issue of Endocrine News.